For over 20 years, Genentech has been committed to CF and connecting you with the medicine you need. We offer programs to help eligible patients get Pulmozyme, regardless of ability to pay.
Pulmozyme Access Solutions®: This program can help eligible patients receive financial support for covering the cost of Pulmozyme.
Download and e-submit the Patient Authorization and Notice of Release of Information (PAN) form.
Pulmozyme Co-pay Card: This co-pay assistance program may help you with the out-of-pocket costs of your Pulmozyme prescription.
Genentech® Access to Care Foundation: The Genentech Access to Care Foundation was established to help qualified patients with unmet medical needs receive proper medical treatment. This resource may be available to help those who are not able to obtain Pulmozyme for financial reasons.
Contact the Genentech Access to Care Foundation by phone, or visit their website to learn more.
Weekdays 6:00 AM to 5:00 PM PST
Pulmozyme (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.
In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.
Pulmozyme should not be used in patients who are allergic to any of its ingredients.
Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.
The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.
The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to <10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
For further information, please see the full Pulmozyme Prescribing Information. If you have questions, please discuss them with your CF Care Team.